-
Vemurafenib (INN), sold
under the
brand name Zelboraf, is a
medication used for the
treatment of late-stage melanoma. It is an
inhibitor of the B-Raf...
- developed. Two of
these drugs,
vemurafenib and dabrafenib, are
approved by FDA for
treatment of late-stage melanoma.
Vemurafenib was the
first approved drug...
-
metastatic melanoma with a BRAF V600E or V600K mutation, in
combination with
vemurafenib. It is also
indicated for the
treatment of
adults with
histiocytic neoplasms...
- [citation needed]
There are two FDA-approved
targeted drugs to
treat ECD.
Vemurafenib, an oral
agent approved in 2019,
targets the BRAF protein. It was approved...
-
Hyperkeratosis can also be
caused by B-Raf
inhibitor drugs such as
Vemurafenib and Dabrafenib. It can be
treated with urea-containing creams, which...
-
Etoposide Teniposide Tafluposide Bortezomib Erlotinib Gefitinib Imatinib Vemurafenib Vismodegib Azacitidine Azathioprine Capecitabine Cladribine Clofarabine...
- and
vemurafenib 720 mg
orally twice daily, or
placebo in
combination with
cobimetinib 60 mg
orally once
daily (21 days on/7 days off) and
vemurafenib 960 mg...
-
monoclonal antibody approved to
treat rheumatoid arthritis. 2011:
Zelboraf (
vemurafenib): For the
treatment of
metastatic melanoma caused by BRAF mutation. 2012:...
- they are
positive for the
specific mutation. BRAF inhibitors, such as
vemurafenib and
dabrafenib and a MEK
inhibitor trametinib are the most effective...
- PARP
inhibitor olaparib,
veliparib -rafenib BRAF
inhibitors sorafenib,
vemurafenib -tinib Tyrosine-kinase
inhibitors erlotinib,
crizotinib -zomib proteasome...
